This Article Full Text Full Text (PDF) All Versions of this Article: 35/11_suppl_1/2632    most recent 01.STR.0000143214.22567.cbv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Moseley, M. Articles by Donnan, G. Search for Related Content PubMed Articles by Moseley, M. Articles by Donnan, G. Related Collections Acute coronary syndromes

(Stroke. 2004;35:2632.)
© 2004 American Heart Association, Inc.

Articles

Multimodality Imaging

Introduction

From the Department of Radiology (M.M.), Stanford University, Stanford, Calif; and the University of Melbourne and National Stroke Research Institute (G.D.), Victoria, Australia.

Correspondence to Dr Michael Moseley, 1291 Welch Road, Lucas Center, P286, Stanford, CA 94305. Email moseley@stanford.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Noninvasive "multimodal" in vivo imaging is not just becoming standard practice in the clinic, but is rapidly changing the evolving field of experimental imaging of genetic expression ("molecular imaging"). The development of multimodality methodology based on nuclear medicine (NM), positron emission tomography (PET) imaging, magnetic resonance imaging (MRI), and optical imaging is the single biggest focus in many imaging and cancer centers worldwide and is bringing together researchers and engineers from the far-ranging fields of molecular pharmacology to nanotechnology engineering. The rapid growth of in vivo multimodality imaging arises from the convergence of established fields of in vivo imaging technologies with molecular and cell biology. The cross-pollination of these disciplines has been accelerated in part by the establishment of the National Institutes of Health NCI P20 and P50 awards, for example, and by the sheer potential of the technology.

Multimodality imaging is widely considered to involve the incorporation of two or more imaging modalities, usually within the setting of a single examination using, for example, dual- or triple-labeled optical or nuclear medicine "reporter" agents or by performing ultrasound or optical studies within the MR, single-photon emission computed tomography (SPECT), or x-ray computed tomography (CT) environment. Clinically, the best example of multimodality imaging is seen in the rapid evolution of PET-SPECT and PET-CT scanner hybrids. The PET modality has developed into perhaps the most used "multimodal" imaging method. The incorporation of PET into single, hybrid, and multimodality units to provide functional (typically from injected F-18DG studies) and anatomic information is becoming . . . [Full Text of this Article]